Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

A research team at Imperial College London (ICL), UK has started animal testing a vaccine against the new coronavirus.

This marks a step ahead of other scientists and companies working to develop a vaccine for the virus.

Research team lead and ICL professor Robin Shattock says approaches are in place to produce the vaccine much faster than previous outbreaks, including SARS epidemic in 2002-2003.

Shattock said: “We have the technology to develop a vaccine with a speed that’s never been realised before. We have successfully generated our novel coronavirus vaccine candidate in the lab, just 14 days from getting the genetic sequence to generating the candidate in the lab.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

If successful, and if the establishment can obtain additional funding, the vaccine should advance into human clinical trials soon.

Coronavirus vaccine by the University of Oxford

Meanwhile, Jenner Institute at the University of Oxford, UK, signed a contract with Italian firm Advent to manufacture the first batch of the new coronavirus vaccine, ChAdOx1 nCoV-19, for clinical testing.

The seed stock of the vaccine, being produced at Clinical Biomanufacturing Facility of the university, will eventually be moved to Advent, which will initially create 1,000 doses for the first clinical trials.

Researchers used adenovirus, which causes common cold-like symptoms, to produce the vaccines.

The adenovirus has been altered into a safer version so as not to reproduce inside the body. Its new genetic code enables coronavirus generation Spike protein after vaccination, resulting in antibody formation to the protein.